4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following research update on MicroRx, its proprietary platform for the discovery of novel live biotherapeutics.

Using its MicroRx platform, the Company has already identified candidates for severe asthma, allergic asthma and rheumatoid arthritis. The Company continues to expand its drug development pipeline and is pleased to report that the Company has identified bacteria that have therapeutically relevant effects in an industry standard model of multiple sclerosis. The preliminary pre-clinical work, conducted externally, showed the prevention of the development of the disease with demonstrably clear efficacy.

Dr. Alex Stevenson, 4D's Chief Scientific Officer, commented "These results are an exciting development in the progress of live biotherapeutics. To potentially treat a disease such as multiple sclerosis with an oral capsule of therapeutically functional bacteria would be a huge step forward in the treatment of this disease." Dr Stevenson further noted "The data from the multiple sclerosis trial provides further validation of MicroRx, our discovery platform, and its potential to rationally identify novel live biotherapeutic candidates for a range of important diseases."